• inhibition of endogenous antagonists with an engineered bmp-2 variant increases bmp-2 efficacy in rat femoral defect healing

    کلمات کلیدی :
    جزئیات بیشتر مقاله
    • تاریخ ارائه: 1392/01/01
    • تاریخ انتشار در تی پی بین: 1392/01/01
    • تعداد بازدید: 626
    • تعداد پرسش و پاسخ ها: 0
    • شماره تماس دبیرخانه رویداد: -
     bone morphogenetic proteins (bmp) have been used successfully by orthopedic clinicians to augment bone healing. however, these osteoinductive proteins must be applied at high concentrations to induce bone formation. the limited therapeutic efficacy may be due to the local expression of bmp antagonists such as noggin that neutralize exogenous and endogenous bmps. if so, inhibiting bmp antagonists may provide an attractive option to augment bmp induced bone formation. the engineered bmp-2 variant l51p is deficient in bmp receptor type i binding, but maintains its affinity for bmp receptor type ii and bmp antagonists including noggin, chordin and gremlin. this modification makes l51p a bmp receptor-inactive inhibitor of bmp antagonists. we implanted β-tricalcium phosphate ceramics loaded with bmp-2 and/or l51p into a critical size defect model in the rat femur to investigate whether the inhibition of bmp antagonist with l51p enhances the therapeutic efficacy of exogenous bmp-2. our study reveals that l51p reduces the demand of exogenous bmp-2 to induce bone healing markedly, without promoting bone formation directly when applied alone.

سوال خود را در مورد این مقاله مطرح نمایید :

با انتخاب دکمه ثبت پرسش، موافقت خود را با قوانین انتشار محتوا در وبسایت تی پی بین اعلام می کنم